The antihypertensive effect of acebutolol was observed in 26 cases of essential hypertension, and following results were obtained. 1) Mean decrease in systolic and diastolic blood pressure by oral acebutolol was 21mmHg and 11mmHg. The results of antihypertensive therapy revealed good control in 30.8%, fair control in 34.6%, poor in 11.5% and failure in 23.1% of the cases. In 65.4% of the cases, good or fair control of hypertension which means drop of diastolic pressure to the level of less than 100mmHg was observed. 2) Mean drop in heart rate was 7/min. 3) Average daily dose was 508+/-171.9mg. 4) The side effect of oral acebutolol was mild gastrointestinal discomfort in two cases.
Acebutolol* ; Blood Pressure ; Heart Rate ; Hypertension

The antihypertensive effect of acebutolol was observed in 26 cases of essential hypertension, and following results were obtained. 1) Mean decrease in systolic and diastolic blood pressure by oral acebutolol was 21mmHg and 11mmHg. The results of antihypertensive therapy revealed good control in 30.8%, fair control in 34.6%, poor in 11.5% and failure in 23.1% of the cases. In 65.4% of the cases, good or fair control of hypertension which means drop of diastolic pressure to the level of less than 100mmHg was observed. 2) Mean drop in heart rate was 7/min. 3) Average daily dose was 508+/-171.9mg. 4) The side effect of oral acebutolol was mild gastrointestinal discomfort in two cases.
Acebutolol* ; Blood Pressure ; Heart Rate ; Hypertension

Serial changes of serum lipids were observed in 28 patients with essential hypertension, administered combination regimen of acebutolo 400mg and hydrochlorothiazide 25mf for up to 24 weeks. The results were as follows. 1) Serum total cholesterol and triglyceride level were varied within -6-5 and -2-7% change respectively which were not significant clinically. 2) High density lipoprotein-cholesterol decreased 5% at 6 weeks, 16% and 17% decrease in 12 and 24 weeks respecitively. The changes were more remarkable in the hyperlipidemic patients. 3) Pretreatment average blood pressure of 174/104mmHg lowered to 144/88 at 6 weeks and normalized to 135/86 at 12 weeks. 4) No adverse reaction were observed except mild weakness and indigestion which did not force the discontinuation of drugs. In summary, the fixed-ratio combination of acebutolol and hydrochlorothiazide was excellent in antihypertensive efficacy and patient's compliance, although decrease in high density lipoprotein-cholesterol demand the physician alert to exert vigilance especially in young hypertensives and hyperlipidemic patient to check serum lipids before and during medication, and to change regimen if metabolic derangement is detected in the view point of primary prevention of coronary heart disease.
Acebutolol* ; Blood Pressure ; Cholesterol ; Compliance ; Coronary Disease ; Dyspepsia ; Humans ; Hydrochlorothiazide ; Hypertension* ; Primary Prevention ; Triglycerides

The phosphorylation of JNK is known to induce insulin resistance in insulin target tissues. The inhibition of JNK-JIP1 interaction, which interferes JNK phosphorylation, becomes a potential target for drug development of type 2 diabetes. To discover the inhibitors of JNK-JIP1 interaction, we screened out 30 candidates from 4320 compound library with In Cell Interaction Trap method. The candidates were further confirmed and narrowed down to five compounds using the FRET method in a model cell. Among those five compounds, Acebutolol showed notable inhibition of JNK phosphorylation and elevation of glucose uptake in diabetic models of adipocyte and liver cell. Structural computation showed that the binding affinity of Acebutolol on the JNK-JIP1 interaction site was comparable to the known inhibitor, BI-78D3. Our results suggest that Acebutolol, an FDA-approved beta blocker for hypertension therapy, could have a new repurposed effect on type 2 diabetes elevating glucose uptake process by inhibiting JNK-JIP1 interaction.
Acebutolol* ; Adipocytes ; Cell Communication ; Diabetes Mellitus ; Drug Evaluation, Preclinical ; Glucose* ; Hypertension ; Insulin ; Insulin Resistance ; Liver ; Methods ; Phosphorylation

BOOP(Bronchiolitis Obliterans Organizing Pneumonia) is an inflammatory reaction that follows damage to the bronchiolar epithelium of the small conducting airways. BOOP is characterized by the pathologic finding of excessive proliferation of granulation tissue within the respiratory bronchioles, alveolar duct and spaces, accompanied by organizing pneumonia. BOOP may result from diverse causes such as toxic fumes, connective tissue disorders, infections, organ transplantation and drugs or appear idiopathically. Drug induced BOOP has been described in association with acebutolol, amiodarone, cephalosporin, bleomycine, tryptophan, gold salts, barbiturates, sulfasalazine, and carbamazepine. Carbamazepine is an iminostilbene derivative that is used as both and anticonvulasnt and pain reliever for pains associated with trigeminal neuralgia. It is structually related to the tricyclic antidepressants. To our knowledge, there have been no previously reported case that has described development of BOOP during carbamazepine treatment in Korea, and only two cases have been reported in the world. We report a case of carbamazepine-induce BOOP with a brief review of literature.
Acebutolol ; Amiodarone ; Antidepressive Agents, Tricyclic ; Barbiturates ; Bleomycin ; Bronchioles ; Bronchiolitis Obliterans* ; Bronchiolitis* ; Carbamazepine* ; Connective Tissue ; Cryptogenic Organizing Pneumonia* ; Epithelium ; Granulation Tissue ; Korea ; Organ Transplantation ; Pneumonia ; Salts ; Sulfasalazine ; Transplants ; Trigeminal Neuralgia ; Tryptophan